Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies.

McCoy LE, Falkowska E, Doores KJ, Le K, Sok D, van Gils MJ, Euler Z, Burger JA, Seaman MS, Sanders RW, Schuitemaker H, Poignard P, Wrin T, Burton DR.

PLoS Pathog. 2015 Aug 12;11(8):e1005110. doi: 10.1371/journal.ppat.1005110. eCollection 2015 Aug.

2.

Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.

Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, de la Peña AT, Cupo A, Julien JP, van Gils M, Lee PS, Peng W, Paulson JC, Poignard P, Burton DR, Moore JP, Sanders RW, Wilson IA, Ward AB.

Immunity. 2014 May 15;40(5):669-80. doi: 10.1016/j.immuni.2014.04.008. Epub 2014 Apr 24.

3.

Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.

Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, Ramirez A, Derking R, van Gils MJ, Liang CH, Mcbride R, von Bredow B, Shivatare SS, Wu CY, Chan-Hui PY, Liu Y, Feizi T, Zwick MB, Koff WC, Seaman MS, Swiderek K, Moore JP, Evans D, Paulson JC, Wong CH, Ward AB, Wilson IA, Sanders RW, Poignard P, Burton DR.

Immunity. 2014 May 15;40(5):657-68. doi: 10.1016/j.immuni.2014.04.009. Epub 2014 Apr 24.

4.

Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data.

Ferguson AL, Falkowska E, Walker LM, Seaman MS, Burton DR, Chakraborty AK.

PLoS One. 2013 Dec 2;8(12):e80562. doi: 10.1371/journal.pone.0080562. eCollection 2013.

5.

Anti-HIV B Cell lines as candidate vaccine biosensors.

Ota T, Doyle-Cooper C, Cooper AB, Huber M, Falkowska E, Doores KJ, Hangartner L, Le K, Sok D, Jardine J, Lifson J, Wu X, Mascola JR, Poignard P, Binley JM, Chakrabarti BK, Schief WR, Wyatt RT, Burton DR, Nemazee D.

J Immunol. 2012 Nov 15;189(10):4816-24. doi: 10.4049/jimmunol.1202165. Epub 2012 Oct 12.

6.

IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.

Nilvebrant J, Dunlop DC, Sircar A, Wurch T, Falkowska E, Reichert JM, Helguera G, Piccione EC, Brack S, Berger S.

MAbs. 2012 Mar-Apr;4(2):153-81. doi: 10.4161/mabs.4.2.19495. Epub 2012 Mar 1.

7.

PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.

Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, Walker LM, Wu X, Seaman MS, Wrin T, Kwong PD, Wyatt RT, Mascola JR, Poignard P, Burton DR.

J Virol. 2012 Apr;86(8):4394-403. doi: 10.1128/JVI.06973-11. Epub 2012 Feb 15.

8.

Broad neutralization coverage of HIV by multiple highly potent antibodies.

Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD; Protocol G Principal Investigators, Koff WC, Wilson IA, Burton DR, Poignard P.

Nature. 2011 Sep 22;477(7365):466-70. doi: 10.1038/nature10373.

9.

Hepatitis C virus soluble E2 in combination with QuilA and CpG ODN induces neutralizing antibodies in mice.

Naarding MA, Falkowska E, Xiao H, Dragic T.

Vaccine. 2011 Apr 5;29(16):2910-7. doi: 10.1016/j.vaccine.2011.02.009. Epub 2011 Feb 21.

PMID:
21338680
10.

Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization.

Falkowska E, Kajumo F, Garcia E, Reinus J, Dragic T.

J Virol. 2007 Aug;81(15):8072-9. Epub 2007 May 16.

11.

L-SIGN (CD209L) isoforms differently mediate trans-infection of hepatoma cells by hepatitis C virus pseudoparticles.

Falkowska E, Durso RJ, Gardner JP, Cormier EG, Arrigale RA, Ogawa RN, Donovan GP, Maddon PJ, Olson WC, Dragic T.

J Gen Virol. 2006 Sep;87(Pt 9):2571-6.

PMID:
16894195

Supplemental Content

Loading ...
Support Center